Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.16
HOLX's Cash to Debt is ranked lower than
89% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.47 vs. HOLX: 0.16 )
Ranked among companies with meaningful Cash to Debt only.
HOLX' s Cash to Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.47 Max: No Debt
Current: 0.16
Equity to Asset 0.29
HOLX's Equity to Asset is ranked lower than
87% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. HOLX: 0.29 )
Ranked among companies with meaningful Equity to Asset only.
HOLX' s Equity to Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.59 Max: 0.88
Current: 0.29
0.22
0.88
Interest Coverage 3.53
HOLX's Interest Coverage is ranked lower than
89% of the 132 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 42.78 vs. HOLX: 3.53 )
Ranked among companies with meaningful Interest Coverage only.
HOLX' s Interest Coverage Range Over the Past 10 Years
Min: 0.55  Med: 2.21 Max: 71.1
Current: 3.53
0.55
71.1
F-Score: 8
Z-Score: 1.38
M-Score: -2.75
WACC vs ROIC
6.48%
8.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 19.37
HOLX's Operating margin (%) is ranked higher than
86% of the 186 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.66 vs. HOLX: 19.37 )
Ranked among companies with meaningful Operating margin (%) only.
HOLX' s Operating margin (%) Range Over the Past 10 Years
Min: -123.18  Med: 8.37 Max: 20.93
Current: 19.37
-123.18
20.93
Net-margin (%) 11.67
HOLX's Net-margin (%) is ranked higher than
78% of the 186 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.06 vs. HOLX: 11.67 )
Ranked among companies with meaningful Net-margin (%) only.
HOLX' s Net-margin (%) Range Over the Past 10 Years
Min: -135.4  Med: -1.5 Max: 12.81
Current: 11.67
-135.4
12.81
ROE (%) 15.78
HOLX's ROE (%) is ranked higher than
82% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.17 vs. HOLX: 15.78 )
Ranked among companies with meaningful ROE (%) only.
HOLX' s ROE (%) Range Over the Past 10 Years
Min: -60.17  Med: -0.73 Max: 15.67
Current: 15.78
-60.17
15.67
ROA (%) 4.44
HOLX's ROA (%) is ranked higher than
62% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.59 vs. HOLX: 4.44 )
Ranked among companies with meaningful ROA (%) only.
HOLX' s ROA (%) Range Over the Past 10 Years
Min: -32.08  Med: -0.35 Max: 9.84
Current: 4.44
-32.08
9.84
ROC (Joel Greenblatt) (%) 85.62
HOLX's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.16 vs. HOLX: 85.62 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HOLX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -369.68  Med: 25.23 Max: 90.76
Current: 85.62
-369.68
90.76
Revenue Growth (3Y)(%) 2.20
HOLX's Revenue Growth (3Y)(%) is ranked lower than
55% of the 150 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.70 vs. HOLX: 2.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HOLX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.7  Med: 10.3 Max: 35.9
Current: 2.2
-7.7
35.9
GuruFocus has detected 2 Warning Signs with Hologic Inc $HOLX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HOLX's 10-Y Financials

Financials (Next Earnings Date: 2017-02-01)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

HOLX Guru Trades in Q4 2015

Jim Simons 1,667,118 sh (New)
Pioneer Investments 147,180 sh (+569.79%)
Steven Cohen 998,300 sh (+320.34%)
RS Investment Management 1,142,810 sh (+24.01%)
Kahn Brothers 1,350,251 sh (+0.61%)
Carl Icahn 28,154,879 sh (unchged)
Prem Watsa Sold Out
Paul Tudor Jones Sold Out
Ken Fisher 47,600 sh (-0.07%)
Vanguard Health Care Fund 5,802,700 sh (-5.80%)
Murray Stahl 15,126 sh (-11.24%)
Joel Greenblatt 384,989 sh (-31.40%)
» More
Q1 2016

HOLX Guru Trades in Q1 2016

Ray Dalio 52,900 sh (New)
Paul Tudor Jones 45,242 sh (New)
Ken Fisher 47,620 sh (+0.04%)
Vanguard Health Care Fund 5,802,700 sh (unchged)
Murray Stahl Sold Out
Carl Icahn Sold Out
Kahn Brothers 1,326,484 sh (-1.76%)
RS Investment Management 924,598 sh (-19.09%)
Pioneer Investments 112,646 sh (-23.46%)
Jim Simons 1,267,918 sh (-23.95%)
Steven Cohen 557,200 sh (-44.19%)
Joel Greenblatt 19,794 sh (-94.86%)
» More
Q2 2016

HOLX Guru Trades in Q2 2016

Robert Olstein 187,000 sh (New)
Leon Cooperman 100,000 sh (New)
Paul Tudor Jones 1,310,684 sh (+2797.05%)
Joel Greenblatt 31,837 sh (+60.84%)
Steven Cohen 715,700 sh (+28.45%)
Vanguard Health Care Fund 7,306,800 sh (+25.92%)
Steven Cohen 55,500 sh (unchged)
Jim Simons Sold Out
Ray Dalio Sold Out
RS Investment Management Sold Out
Kahn Brothers 1,276,984 sh (-3.73%)
Ken Fisher 37,600 sh (-21.04%)
Pioneer Investments 58,312 sh (-48.23%)
» More
Q3 2016

HOLX Guru Trades in Q3 2016

George Soros 7,236 sh (New)
Jim Simons 590,018 sh (New)
Joel Greenblatt 103,903 sh (+226.36%)
Steven Cohen 1,315,600 sh (+83.82%)
Pioneer Investments 85,816 sh (+47.17%)
Robert Olstein 187,000 sh (unchged)
Ken Fisher Sold Out
Leon Cooperman Sold Out
Kahn Brothers 1,234,514 sh (-3.33%)
Vanguard Health Care Fund 6,896,300 sh (-5.62%)
Paul Tudor Jones 1,200,000 sh (-8.44%)
» More
» Details

Insider Trades

Latest Guru Trades with HOLX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 334517    SIC: 3844
Compare:NYSE:MTD, NYSE:WAT, OTCPK:OCPNF, NYSE:RMD, NAS:XRAY, NYSE:COO, OTCPK:TRUMY, OTCPK:CLPBY, NYSE:WST, NYSE:STE, NYSE:BCR, OTCPK:GNGBF, NYSE:HRC, NYSE:CMD, OTCPK:ANSLY, NAS:PODD, NAS:ICUI, NYSE:HAE, NYSE:HYH, NAS:NXTM » details
Traded in other countries:HO1.Germany,
Hologic Inc is a developer, manufacturer and supplier of medical imaging systems and diagnostic and surgical products serving the healthcare needs of women.

Hologic Inc was incorporated in Massachusetts in October 1985. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates in four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. It offers diagnostic products which are used to aid in the diagnosis of human diseases and screen donated human blood and plasma. Its primary diagnostics products include its Aptima family of assays, which run on its instrumentation systems (Panther and Tigris), its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, or STDs, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus, or HPV, and Trichomonas vaginalis, the parasite that causes trichomoniasis. The ThinPrep System is used in cytology applications, such as cervical cancer screening, and the Rapid Fetal Fibronectin Test assists physicians in assessing the risk of pre-term birth. In blood screening, the Company develops and manufactures the Procleix family of assays, which are used to detect various infectious diseases. The Procleix blood screening assays also run on its Panther and Tigris systems. These blood screening products are marketed by its blood screening collaborator, Grifols S.A., or Grifols, under Grifols' trademarks. The Breast Health products include a portfolio of breast imaging and related products and accessories, including digital mammography systems, computer-aided detection, or CAD, for mammography and minimally invasive breast biopsy devices, breast biopsy site markers, and breast biopsy guidance systems. Its breast imaging platform, Dimensions, utilizes a technology called tomosynthesis to produce 3D images that show multiple contiguous slice images of the breast, which it refers to as the Genius 3D Mammography exam, as well as conventional 2D full field digital mammography images. Its clinical results for FDA approval demonstrated that conventional 2D digital mammography with the addition of 3D tomosynthesis is superior to 2D digital mammography alone for both screening and diagnostics. The GYN Surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The NovaSure system involves a trans-cervical procedure for the treatment of abnormal uterine bleeding. The MyoSure system is a tissue removal device that is designed to provide incision-less removal of fibroids, polyps, and other pathology within the uterus. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers that assess the bone density of fracture sites; and mini C-arm imaging systems that assist in performing minimally invasive surgical procedures on a patient's extremities, such as the hand, wrist, knee,

Top Ranked Articles about Hologic Inc

Carl Icahn Continues to Reduce Position in Hologic Guru slashes more than 3 million shares from his portfolio
Guru Carl Icahn (Trades, Portfolio) reduced his position in Hologic Inc. (NASDAQ:HOLX), slashing 3,346,767 shares from his portfolio Monday. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 33.91
HOLX's P/E(ttm) is ranked lower than
65% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.27 vs. HOLX: 33.91 )
Ranked among companies with meaningful P/E(ttm) only.
HOLX' s P/E(ttm) Range Over the Past 10 Years
Min: 25.41  Med: 60.24 Max: 472.67
Current: 33.91
25.41
472.67
Forward P/E 18.62
HOLX's Forward P/E is ranked higher than
74% of the 38 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.83 vs. HOLX: 18.62 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 33.91
HOLX's PE(NRI) is ranked lower than
67% of the 113 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.88 vs. HOLX: 33.91 )
Ranked among companies with meaningful PE(NRI) only.
HOLX' s PE(NRI) Range Over the Past 10 Years
Min: 25.41  Med: 60.21 Max: 472.67
Current: 33.91
25.41
472.67
Price/Owner Earnings (ttm) 18.26
HOLX's Price/Owner Earnings (ttm) is ranked higher than
70% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.08 vs. HOLX: 18.26 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
HOLX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.77  Med: 25.13 Max: 311.63
Current: 18.26
10.77
311.63
P/B 5.10
HOLX's P/B is ranked lower than
74% of the 177 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.15 vs. HOLX: 5.10 )
Ranked among companies with meaningful P/B only.
HOLX' s P/B Range Over the Past 10 Years
Min: 0.59  Med: 2.01 Max: 9.6
Current: 5.1
0.59
9.6
P/S 3.99
HOLX's P/S is ranked lower than
62% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.74 vs. HOLX: 3.99 )
Ranked among companies with meaningful P/S only.
HOLX' s P/S Range Over the Past 10 Years
Min: 1.45  Med: 2.92 Max: 7.52
Current: 3.99
1.45
7.52
PFCF 16.36
HOLX's PFCF is ranked higher than
80% of the 76 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.09 vs. HOLX: 16.36 )
Ranked among companies with meaningful PFCF only.
HOLX' s PFCF Range Over the Past 10 Years
Min: 6.45  Med: 15.01 Max: 514.17
Current: 16.36
6.45
514.17
POCF 14.32
HOLX's POCF is ranked higher than
62% of the 96 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.77 vs. HOLX: 14.32 )
Ranked among companies with meaningful POCF only.
HOLX' s POCF Range Over the Past 10 Years
Min: 5.45  Med: 13.09 Max: 140.85
Current: 14.32
5.45
140.85
EV-to-EBIT 24.16
HOLX's EV-to-EBIT is ranked lower than
57% of the 116 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.51 vs. HOLX: 24.16 )
Ranked among companies with meaningful EV-to-EBIT only.
HOLX' s EV-to-EBIT Range Over the Past 10 Years
Min: -137.4  Med: 27.75 Max: 153.7
Current: 24.16
-137.4
153.7
EV-to-EBITDA 13.30
HOLX's EV-to-EBITDA is ranked higher than
66% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.65 vs. HOLX: 13.30 )
Ranked among companies with meaningful EV-to-EBITDA only.
HOLX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -344.2  Med: 13.3 Max: 100.6
Current: 13.3
-344.2
100.6
Current Ratio 1.47
HOLX's Current Ratio is ranked lower than
76% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.46 vs. HOLX: 1.47 )
Ranked among companies with meaningful Current Ratio only.
HOLX' s Current Ratio Range Over the Past 10 Years
Min: 1.34  Med: 2.49 Max: 7.31
Current: 1.47
1.34
7.31
Quick Ratio 1.17
HOLX's Quick Ratio is ranked lower than
66% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.65 vs. HOLX: 1.17 )
Ranked among companies with meaningful Quick Ratio only.
HOLX' s Quick Ratio Range Over the Past 10 Years
Min: 1.04  Med: 1.97 Max: 6.57
Current: 1.17
1.04
6.57
Days Inventory 81.07
HOLX's Days Inventory is ranked higher than
76% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 123.20 vs. HOLX: 81.07 )
Ranked among companies with meaningful Days Inventory only.
HOLX' s Days Inventory Range Over the Past 10 Years
Min: 65.34  Med: 88.04 Max: 108.2
Current: 81.07
65.34
108.2
Days Sales Outstanding 57.59
HOLX's Days Sales Outstanding is ranked higher than
60% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.72 vs. HOLX: 57.59 )
Ranked among companies with meaningful Days Sales Outstanding only.
HOLX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.15  Med: 60.73 Max: 75.51
Current: 57.59
56.15
75.51
Days Payable 45.11
HOLX's Days Payable is ranked higher than
50% of the 143 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.55 vs. HOLX: 45.11 )
Ranked among companies with meaningful Days Payable only.
HOLX' s Days Payable Range Over the Past 10 Years
Min: 21.81  Med: 27.28 Max: 45.11
Current: 45.11
21.81
45.11

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.70
HOLX's 3-Year Average Share Buyback Ratio is ranked higher than
66% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. HOLX: -0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HOLX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -42.6  Med: -6.1 Max: -0.7
Current: -0.7
-42.6
-0.7

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.67
HOLX's Price/Projected FCF is ranked higher than
58% of the 84 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.84 vs. HOLX: 1.67 )
Ranked among companies with meaningful Price/Projected FCF only.
HOLX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.41  Med: 1.48 Max: 5.67
Current: 1.67
0.41
5.67
Price/Median PS Value 1.37
HOLX's Price/Median PS Value is ranked lower than
71% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. HOLX: 1.37 )
Ranked among companies with meaningful Price/Median PS Value only.
HOLX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.15  Med: 0.87 Max: 1.55
Current: 1.37
0.15
1.55
Earnings Yield (Greenblatt) (%) 4.09
HOLX's Earnings Yield (Greenblatt) (%) is ranked higher than
67% of the 186 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.60 vs. HOLX: 4.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HOLX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.7  Med: 2.8 Max: 7.2
Current: 4.09
0.7
7.2
Forward Rate of Return (Yacktman) (%) 26.58
HOLX's Forward Rate of Return (Yacktman) (%) is ranked higher than
85% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.19 vs. HOLX: 26.58 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
HOLX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 0.1  Med: 6.8 Max: 72.6
Current: 26.58
0.1
72.6

More Statistics

Revenue (TTM) (Mil) $2,833
EPS (TTM) $ 1.16
Beta0.67
Short Percentage of Float2.20%
52-Week Range $31.84 - 41.01
Shares Outstanding (Mil)279.24

Analyst Estimate

Sep17 Sep18 Sep19
Revenue (Mil $) 2,877 2,966 3,101
EPS ($) 2.07 2.20 2.46
EPS w/o NRI ($) 2.07 2.20 2.46
EPS Growth Rate
(3Y to 5Y Estimate)
6.79%
Dividends Per Share ($)
» More Articles for HOLX

Headlines

Articles On GuruFocus.com
Robert Olstein's Best Performing Investments Include eBay Aug 14 2016 
Carl Icahn's Stakes with Positive Return Aug 04 2016 
Edward Owens Top 2nd Quarter Investments Aug 03 2016 
Carl Icahn's Largest Trades of the 2nd Quarter Jul 19 2016 
Carl Icahn Continues to Reduce Position in Hologic Apr 07 2016 
Investment Ideas Trading With Very Low P/S Ratio Jan 13 2016 
Carl Icahn Makes Big Transactions in 3rd Quarter Jan 03 2016 
Kahn Brothers' Largest Sales During 3rd Quarter Dec 22 2015 
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 
Amazon Among Ken Fisher's Best Performing Stocks Oct 19 2015 

More From Other Websites
Is a Surprise in Store for Hologic (HOLX) in Q1 Earnings? Jan 23 2017
Coverage initiated on Hologic by Deutsche Bank Jan 18 2017
The Zacks Analyst Blog Highlights: Intuitive Surgical, Stryker and Hologic Jan 18 2017
3 Medical Device Stocks Likely to Beat Earnings Estimates Jan 17 2017
Hologic Takes Center Stage at Conference (HOLX) Jan 10 2017
Hologic to Announce Financial Results for the First Quarter of Fiscal 2017 on Wednesday, February 1,... Jan 05 2017
Hologic to Announce Financial Results for the First Quarter of Fiscal 2017 on Wednesday, February 1,... Jan 05 2017
Hologic Appoints President of EMEA and Canada, Completing International Leadership Team Jan 04 2017
Hologic Appoints President of EMEA and Canada, Completing International Leadership Team Jan 04 2017
Hologic (HOLX) Receives PMA for Aptima HIV-1 Quant Assay Jan 04 2017
FDA Grants PMA Approval for Hologic's Aptima® HIV-1 Quant Assay Jan 03 2017
FDA Grants PMA Approval for Hologic's Aptima® HIV-1 Quant Assay Jan 03 2017
Stock picks and pans for 2017 Dec 21 2016
Hologic to Present at the 35th Annual J.P. Morgan Healthcare Conference Dec 20 2016
Piper Jaffray's 2017 S&P 500 target: 2,424 Dec 19 2016
Hologic (HOLX) to Divest Blood Screening Business to Grifols Dec 19 2016
Amy Wendell Elected to Hologic Board of Directors Dec 16 2016
HOLOGIC INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Dec 16 2016
Amy Wendell Elected to Hologic Board of Directors Dec 16 2016
Hologic Still A Buy After Getting 'Lofty' Price For Blood-Screening Unit Dec 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)